Craft

Lonza

Stock Price

CHF446.8

2024-02-12

Market Capitalization

CHF33.2 B

2024-02-12

Revenue

CHF6.2 B

FY, 2022

Lonza Summary

Company Summary

Overview
Lonza Group is a company that supplies active ingredients, chemical intermediates, and biotechnology solutions to the pharmaceutical and agrochemical industries. It operates through four segments: Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients. The Biologics segment is a contract development and manufacturing partner for biopharmaceuticals, serving customers for clinical and commercial manufacturing needs throughout the product lifecycle. The Small Molecules division operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies, it also offers specialty raw materials and enabling technology solutions in core target markets, including cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing. The Capsules & Health Ingredients segment provides capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical companies.
Type
Public
Status
Active
Founded
1897
HQ
Basel, CH | view all locations
Website
https://www.lonza.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Albert M. Baehny

    Albert M. Baehny, Chief Executive Officer ad interim and Chairman

    • Philippe Deecke

      Philippe Deecke, Chief Financial Officer and Member of the Executive Committee

    • Ulrike Kaeppler

      Ulrike Kaeppler, Chief Human Resources Officer and Member of the Executive Committee

    • Daniel Palmacci

      Daniel Palmacci, President, Cell & Gene and Member of the Executive Committee

    Operating MetricsView all

    Capsules Produced (Pharma and Biotech)

    250B
    8.7%

    FY, 2021

    Clinical Development Programs (Pharma and Biotech)

    1K
    25.0%

    FY, 2021

    Patent Families

    357
    37.3%

    FY, 2021

    LocationsView all

    58 locations detected

    • Basel, BS HQ

      Switzerland

      Münchensteinerstrasse 38

    • Bend, OR

      United States

      63045 NE Corporate Pl

    • Cambridge, MA

      United States

      50 Hampshire St

    • Cohasset, MN

      United States

      1101 NW 3rd St

    • Greenwood, SC

      United States

      535 Emerald Rd N

    • Houston, TX

      United States

      14905 Kirby Dr

    and 52 others

    Lonza Financials

    Summary Financials

    Revenue (H1, 2023)
    CHF3.1B
    Gross profit (H1, 2023)
    CHF1.1B
    Net income (H1, 2023)
    CHF411.0M
    Cash (H1, 2023)
    CHF1.7B
    EBIT (H1, 2023)
    CHF527.0M
    Enterprise value
    $34.4B

    Footer menu